top of page

Access, Ideas, Clarity

A leading virtual platform providing investors with direct access to innovative companies, management teams and thought leaders

What This Means:

This series is designed to provide investors with context to press releases directly from company management teams. It also provides the opportunity for companies to communicate directly to investors and elaborate on recent key news and highlight value driving milestones.

AUTONOMIX LOGO_STACKED COLOR.png
GRI_ LOGO SELECT_Color.png

May 23, 2024

Autonomix Preclinical Study Successfully Demonstrates That Nerve Ablation Can Slow Tumor Metastasis in Pancreatic Cancer

May 22, 2024

Positive Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

Moleculin_Logo_Color.png

April 25, 2024

The Annamycin Opportunity

JTC_VI_Webcast_AREC_edited.png
Artboard 1.png

April 25, 2024

March 15, 2024

ReElement Technologies' Certificate of Occupancy for Marion, Indiana Critical Mineral Refining Supersite

Positive Topline Efficacy Data Showing Significant Clinical Improvement from enVVeno Medical’s VenoValve® Pivotal Trial 

Moleculin_Logo_Color.png

February 29, 2024

A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 3 of 3)

Moleculin_Logo_Color.png
Moleculin_Logo_Color.png

February 15, 2024

February 22, 2024

A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 2 of 3)

A Major Inflection Point - The Moleculin Opportunity in 2024 and Beyond Series (Part 1 of 3)

XBIO_logo-01.png

February 12, 2024

Xenetic Biosciences Highlights Encouraging Recently Reported Preclinical Data on Innovative DNase I Oncology Platform

AUTONOMIX LOGO_HORIZONTAL COLOR.png

January 31, 2024

$8,000,000 Transaction for Exclusive Worldwide Rights to Technology for Cardiology Field Use –
Over 100 patents in portfolio

AIM_Logo_Color_01.07.22.png

February 09, 2024

AIM ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen® for the Treatment of Post-COVID Conditions

Palisade Bio_Logos(4.22)_Logo_HOR.png

January 29, 2024

Palisade Bio Reports Positive Preclinical Data of Lead Program PALI-2108 at the 2024 Crohn's & Colitis Congress

JTC_VI_Webcast_AREC.png

January 9, 2024

American Resources Corporation's ReElement Technologies Adds Former United States Ambassador Mark Gilbert to Board of Directors

TuHURA_DigitalLogo_FullColor.png

January 4, 2024

Morphogenesis, Inc. Announces Corporate Rebranding to TuHURA Biosciences, Inc. and Provides a
Business Overview 

JTC_VI_Webcast_AREC.png

January 3, 2024

American Resources Corporation's ReElement Technologies Adds Former CIA Senior Executive Kevin Higgins to Board of Directors

GRI_ LOGO SELECT_Color.png

December 5, 2023

GRI Bio Commences Patient Enrollment in Phase 2a Biomarker Study Evaluating Lead Program GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis ("IPF")

JTC_VI_Webcast_CNSP.png

December 21, 2023

CNS Pharmaceuticals Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin

AIM_Logo_Color_01.07.22.png

November 27, 2023

AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents

GRI_ LOGO SELECT_Color.png

November 27, 2023

FDA Clearance of IND for Lead Program GRI-0621, a Type 1 Invariant (“iNKT”) Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

Moleculin_Logo_Color.png

November 20, 2023

Next Generation Anthracycline

Artboard 1.png

November 14, 2023

Full Enrollment for VenoValve U.S. Pivotal Trial

November, 1, 2023

GRI Bio Announces Partnership with the Respiratory Translational Research Collaboration to Advance Leading NKT Regulation Technology Targeting Earlier in the Inflammatory Cascade to Modulate Disease Progression

NKGen-Biotech.jpeg

October, 30, 2023

NKGen Biotech Receives FDA Clearance of IND for SNK01 NK Cell Therapy to Treat Moderate Alzheimer's Disease

JTC_VI_Webcast_CNSP.png

October, 18, 2023

Continuing Rapid Pace of
Enrollment with 229 Patients Enrolled

Moleculin_Logo_Color.png

October, 17, 2023

Moleculin Doses First Patient in
Phase 2 Study for AML

CYTH_ColorLogo-01.png

September 27, 2023

Cyclo Therapeutics, Inc. and Applied Molecular Transport Inc. Enter into a Definitive Merger Agreement.

JTC_VI_Webcast_AREC.png

September 8, 2023

AREC's ReElement Technologies Expands Executive Team

August 24, 2023

Recent Clinical Update on Potentially Pivotal Study of Berubicin for GBM

GRI Bio Enters into Asset Purchase Agreement for Sale of Legacy Asset, ADAIR

August 23, 2023

August 7, 2023

GRI Bio Presents Encouraging Preclinical Data of GRI-0803 in Lupus Nephritis

Contat Us
bottom of page